前沿生物：2027年计划推动1-2款小核酸产品完成IND申报

Core Viewpoint - The company plans to advance multiple research and development milestones over the next two years, focusing on existing business segments and core pipelines to establish a solid foundation for long-term growth [2] Short-term Strategy (3-5 years) - The company will focus on three main areas: 1. Deepening its core business in HIV, leveraging its R&D team and technology to develop new products that meet differentiated clinical needs, aiming to advance a new innovative drug into the PCC stage [2] 2. Advancing the approval of high-end generic drugs to enhance cash flow, which will support innovative R&D [2] 3. Prioritizing the development of small nucleic acid innovative drugs while exploring new products that align with its technological capabilities and production capacity [2] Long-term Strategy (5-10 years) - The company will dynamically adjust its strategic layout based on its development stage and global trends in innovative drug technology, with the core goal of becoming a sustainable biopharmaceutical enterprise that continuously creates value for shareholders [2] R&D Focus Areas - In the high-end generic drug sector, the company plans to launch two products targeting the U.S. and Chinese markets within the next two years to provide cash flow support [2] - In the HIV sector, the company aims to continue developing differentiated products, striving to introduce one new innovative drug [2] - In the small nucleic acid field, the company is focusing on advancing four pipelines (FB7013, FB7011, FB7023, FB7033) and aims to complete IND submissions for one of FB7023/FB7033, while also pushing early-stage liver-targeted delivery products to the PCC stage [2]